Abstracts tagged "T-Regulatory Cells and interleukins (IL)"

Abstract Number: 1583 • 2018 ACR/ARHP Annual Meeting
Low-Dose IL-2 Promotes the Proliferation of Peripheral Regulatory T Cells in Primary Sjogren’s Syndrome to Restore Its Balances with Pro-Inflammatory Lymphocytes
Miao Miao¹, Zhenye Hao¹, Yingying Guo¹, Xiaoying Zhang¹, Sheng-Xiao Zhang¹, Jing Luo², Jinfang Zhao³, Chong Gao⁴ and Xiao-Feng Li⁵, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²the Second Hospital of Shanxi Medical University, Taiyuan, China, ³The Shanxi Medical University, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ⁵Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: To investigate the effect of low-dose IL-2 on the balance of Treg with Teff and other pro-inflammatory lymphocytes in peripheral blood of pSS patients.Methods:…
Abstract Number: 659 • 2016 ACR/ARHP Annual Meeting
Low Dose IL-2 Therapy Can Restore the Balance of Th17 and Treg Cells in Refractory Patients with Sjogren’s Syndrome
Miao Miao¹, Shengxiao Zhang¹, Xiao-Qing Liu¹, Xiaoyan Wu², Chong Gao³ and Xiao-Feng Li², ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ³Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women’s Hospital/Children’s Hospital Boston, Harvard Medical School, Boston, MA, Cambridge, MA
Background/Purpose: The therapy for sjogren’s syndrome (SS) focuses on biological agents, immune inhibitors and glucocorticoid which can’t correct the problem of unbalance of Th17 and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].